Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who founded Epygenix Therapeutics, Inc. to develop precision medicine for rare intractable genetic epilepsy. He also founded (1) Polaryx Therapeutics, Inc to develop patient-friendly oral medications for Batten disease, a devastating neurodegenerative pediatric genetic disorder and (2) Focus Therapeutics, L.L.C. to provide a catalytic role between US and Asian Pacific biotechnology, transactions, and partnerships. He has an extensive experience in R&D, deal making, business development, and has consulted for several top-notch health care Venture Capital firms, global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He also consulted for Korean biotechs, Venture Capital firms, and research institutes, including Korea Research Institute of Chemical Technology (KRICT), CHA Biotech, and CMG Pharma.
Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.
He obtained his B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.